SCHEMBL2212129

SCHEMBL2212129

CC(C)(C)N(C(=O)O)C(C)(CN)Cc1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.43
CYP1A2 P05177 2/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
HIF1A Q16665 1/20 0.43
RECQL P46063 1/20 0.43
SLC6A2 P23975 1/20 0.43
TAAR1 Q96RJ0 1/20 0.43
MAPK1 P28482 1/20 0.42
MEN1 O00255 4/20 0.42
KMT2A Q03164 4/20 0.42
HTT P42858 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
LMNA P02545 2/20 0.40
NPC1 O15118 3/20 0.40
RAB9A P51151 3/20 0.40
RIPK1 Q13546 2/20 0.40
ALDH1A1 P00352 2/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
NPY5R Q15761 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2023058 0.85 MEN1 (0.43) CYP3A4CYP1A2SMN1; SMN2HIF1ARECQL
SCHEMBL3595900 0.85 MEN1 (0.43) CYP3A4CYP1A2SMN1; SMN2HIF1ARECQL
SCHEMBL2215130 0.79 MMP8 (0.43) CYP3A4SMN1; SMN2MEN1KMT2AHTT
SCHEMBL2873986 0.78 MEN1 (0.38) CYP3A4SMN1; SMN2HIF1ASLC6A2TAAR1
SCHEMBL3600883 0.76 CYP3A4 (0.40) CYP3A4CYP1A2SMN1; SMN2HIF1ARECQL
SCHEMBL2024172 0.76 CYP3A4 (0.40) CYP3A4CYP1A2SMN1; SMN2HIF1ARECQL
SCHEMBL2349672 0.75 MEN1 (0.43) CYP3A4CYP1A2SMN1; SMN2HIF1ARECQL
SCHEMBL2026162 0.74 MEN1 (0.45) CYP3A4CYP1A2SMN1; SMN2HIF1ARECQL
SCHEMBL2025505 0.74 MEN1 (0.45) CYP3A4CYP1A2SMN1; SMN2HIF1ARECQL
SCHEMBL19384865 0.73 TRPA1 (0.42) CYP3A4SMN1; SMN2HIF1ASLC6A2TAAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1689713-B1 BENZYLETHER AND BENZYLAMINO BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER S DISEASE MERCK SHARP & DOHME (US) 2011-07-27 EP disclosed
US-20070088165-A1 preventing the formation of insoluble A beta and arresting the production of A beta; beta-site amyloid precursor protein-cleaving enzyme; 3-[(2-amino-2-methyl-3-phenylpropoxy)methyl]-N-[(1R)-1-(4-fluorophenyl)ethyl]-[methyl(methylsulfonyl)amino]benzamide MERCK SHARP & DOHME LLC 2007-04-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070088165-A1 preventing the formation of insoluble A beta and arresting the production of A beta; beta-site amyloid precursor protein-cleaving enzyme; 3-[(2-amino-2-methyl-3-phenylpropoxy)methyl]-N-[(1R)-1-(4-fluorophenyl)ethyl]-[methyl(methylsulfonyl)amino]benzamide BACE1, BACE2, APP CYP3A4 1143/4885CYP1A2 513/4885SMN1; SMN2 356/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.